source
- AI monitoring tool could generate up to 82-fold ROI in phase-3 oncology trials, study findsAn analysis by the Tufts Center for the Study of Drug Development found that an artificial-intelligence clinical monitoring agent can produce an estimated 82-fold return on investment in phase-3 on…
- Definium's LSD pill shows significant anxiety reduction in Phase 3 trialDefinium Therapeutics announced results of a Phase 3 trial testing its LSD‑based pill DT120 in patients with generalized anxiety disorder. The study enrolled 214 participants who received a single…